Skip to main content

Advertisement

SpringerLink
Log in

Multimodal Therapy for Sinonasal Malignancies: Updates and Review of Current Treatment

  • Head and Neck Cancer (CP Rodriguez, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Sinonasal malignancies pose a significant challenge in management due to their low incidence, biologic diversity, and significant symptom burden. Even though surgery remains the primary therapeutic modality, a multi-modality approach has been shown to benefit a significant proportion of patients and its success depends largely on stage and histologic type. Non-surgical approaches such as novel radiation approaches as well as intensification with systemic therapy hold promise in altering the organ preservation rate as well as overall survival for patients. Practice changing randomized trials to test these novel modalities are overdue and desperately needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Roush GC. Epidemiology of cancer of the nose and paranasal sinuses: current concepts. Head Neck Surg. 1979;2(1):3–11.

    Article  CAS  Google Scholar 

  2. Muir CS, Nectoux J. Descriptive epidemiology of malignant neoplasms of nose, nasal cavities, middle ear and accessory sinuses. Clin Otolaryngol Allied Sci. 1980;5(3):195–211.

    Article  CAS  Google Scholar 

  3. Maghami E, Kraus DH. Cancer of the nasal cavity and paranasal sinuses. Expert Rev Anticancer Ther. 2004;4(3):411–24. https://doi.org/10.1586/14737140.4.3.411.

    Article  PubMed  Google Scholar 

  4. Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck. 2012;34(6):877–85. https://doi.org/10.1002/hed.21830.

    Article  PubMed  Google Scholar 

  5. Zheng W, McLaughlin JK, Chow WH, Chien HT, Blot WJ. Risk factors for cancers of the nasal cavity and paranasal sinuses among white men in the United States. Am J Epidemiol. 1993;138(11):965–72. https://doi.org/10.1093/oxfordjournals.aje.a116816.

    Article  CAS  PubMed  Google Scholar 

  6. El-Mofty SK, Lu DW. Prevalence of high-risk human papillomavirus DNA in nonkeratinizing (cylindrical cell) carcinoma of the sinonasal tract: a distinct clinicopathologic and molecular disease entity. Am J Surg Pathol. 2005;29(10):1367–72.

    Article  Google Scholar 

  7. Bhattacharyya N. Factors affecting survival in maxillary sinus cancer. J Oral Maxillofac Surg. 2003;61(9):1016–21. https://doi.org/10.1016/s0278-2391(03)00313-6.

    Article  PubMed  Google Scholar 

  8. Torjussen W. Occupational nasal cancer caused by nickel and nickel compounds. Rhinology. 1985;23(2):101–5.

    CAS  PubMed  Google Scholar 

  9. Luce D, Leclerc A, Morcet JF, Casal-Lareo A, Gerin M, Brugere J, et al. Occupational risk factors for sinonasal cancer: a case-control study in France. Am J Ind Med. 1992;21(2):163–75.

    Article  CAS  Google Scholar 

  10. Schwaab G, Julieron M, Janot F. Epidemiology of cancers of the nasal cavities and paranasal sinuses. Neurochirurgie. 1997;43(2):61–3.

    CAS  PubMed  Google Scholar 

  11. Devaraja K, Sikka K, Kumar R, Thakar A. Sinonasal malignancies: long term follow up after surgical management-an analysis of outcomes. Indian J Otolaryngol Head Neck Surg. 2015;67(1):28–33. https://doi.org/10.1007/s12070-014-0742-2.

    Article  CAS  PubMed  Google Scholar 

  12. Dulguerov P, Allal AS. Nasal and paranasal sinus carcinoma: how can we continue to make progress? Curr Opin Otolaryngol Head Neck Surg. 2006;14(2):67–72. https://doi.org/10.1097/01.moo.0000193177.62074.fd.

    Article  PubMed  Google Scholar 

  13. Sanderson RJ, Ironside JA. Squamous cell carcinomas of the head and neck. Bmj. 2002;325(7368):822–7. https://doi.org/10.1136/bmj.325.7368.822.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Ansa B, Goodman M, Ward K, Kono SA, Owonikoko TK, Higgins K, et al. Paranasal sinus squamous cell carcinoma incidence and survival based on surveillance, epidemiology, and end results data, 1973 to 2009. Cancer. 2013;119(14):2602–10. https://doi.org/10.1002/cncr.28108.

    Article  PubMed  Google Scholar 

  15. Carlton DA, David Beahm D, Chiu AG. Sinonasal malignancies: endoscopic treatment outcomes. Laryngoscope Investig Otolaryngol. 2019;4(2):259–63. https://doi.org/10.1002/lio2.249.

    Article  PubMed  PubMed Central  Google Scholar 

  16. • Husain Q, Joshi RR, Cracchiolo JR, Roman BR, Ganly I, Tabar V, et al. Surgical management patterns of sinonasal malignancy: a population-based study. J Neurol Surg B Skull Base. 2019;80(4):371–9. https://doi.org/10.1055/s-0038-1675233 Assessment of over 10,000 patients from National Cancer Data Base showing sinonasal cancers managed with endoscopic surgery had comparable outcomes to open resection.

    Article  PubMed  Google Scholar 

  17. Nicolai P, Battaglia P, Bignami M, Bolzoni Villaret A, Delu G, Khrais T, et al. Endoscopic surgery for malignant tumors of the sinonasal tract and adjacent skull base: a 10-year experience. Am J Rhinol. 2008;22(3):308–16. https://doi.org/10.2500/ajr.2008.22.3170.

    Article  PubMed  Google Scholar 

  18. Higgins TS, Thorp B, Rawlings BA, Han JK. Outcome results of endoscopic vs craniofacial resection of sinonasal malignancies: a systematic review and pooled-data analysis. Int Forum Allergy Rhinol. 2011;1(4):255–61. https://doi.org/10.1002/alr.20051.

    Article  PubMed  Google Scholar 

  19. Wellman BJ, Traynelis VC, McCulloch TM, Funk GF, Menezes AH, Hoffman HT. Midline anterior craniofacial approach for malignancy: results of en bloc versus piecemeal resections. Skull Base Surg. 1999;9(1):41–6. https://doi.org/10.1055/s-2008-1058171.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Lango MN, Topham NS, Perlis CS, Flieder DB, Weaver MW, Turaka A, et al. Surgery in the multimodality treatment of sinonasal malignancies. Curr Probl Cancer. 2010;34(5):304–21. https://doi.org/10.1016/j.currproblcancer.2010.07.001.

    Article  PubMed  Google Scholar 

  21. Sayed Z, Migliacci JC, Cracchiolo JR, Barker CA, Lee NY, McBride SM, et al. Association of surgical approach and margin status with oncologic outcomes following gross total resection for sinonasal melanoma. JAMA Otolaryngol Head Neck Surg. 2017;143(12):1220–7. https://doi.org/10.1001/jamaoto.2017.2011.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Varelas AN, Eggerstedt M, Ganti A, Tajudeen BA. Epidemiologic, prognostic, and treatment factors in sinonasal diffuse large B-cell lymphoma. Laryngoscope. 2019;129(6):1259–64. https://doi.org/10.1002/lary.27639.

    Article  PubMed  Google Scholar 

  23. Goepfert H. The vex and fuss about nasal vestibule cancer. Head Neck. 1999;21(5):383–4.

    Article  CAS  Google Scholar 

  24. Thorup C, Sebbesen L, Dano H, Leetmaa M, Andersen M, Buchwald C, et al. Carcinoma of the nasal cavity and paranasal sinuses in Denmark 1995–2004. Acta Oncol. 2010;49(3):389–94. https://doi.org/10.3109/02841860903428176.

    Article  PubMed  Google Scholar 

  25. Wang K, Zanation AM, Chera BS. The role of radiation therapy in the management of sinonasal and ventral skull base malignancies. Otolaryngol Clin N Am. 2017;50(2):419–32. https://doi.org/10.1016/j.otc.2016.12.014.

    Article  Google Scholar 

  26. Huang D, Xia P, Akazawa P, Akazawa C, Quivey JM, Verhey LJ, et al. Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2003;56(1):158–68. https://doi.org/10.1016/s0360-3016(03)00080-4.

    Article  PubMed  Google Scholar 

  27. Dirix P, Vanstraelen B, Jorissen M, Vander Poorten V, Nuyts S. Intensity-modulated radiotherapy for sinonasal cancer: improved outcome compared to conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78(4):998–1004. https://doi.org/10.1016/j.ijrobp.2009.09.067.

    Article  PubMed  Google Scholar 

  28. Patel SH, Wang Z, Wong WW, Murad MH, Buckey CR, Mohammed K, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. Lancet Oncol. 2014;15(9):1027–38. https://doi.org/10.1016/s1470-2045(14)70268-2.

    Article  CAS  PubMed  Google Scholar 

  29. Ghorbani M, Jia SB, Khosroabadi M, Sadoughi HR, Knaup C. Evaluation of the effect of soft tissue composition on the characteristics of spread-out Bragg peak in proton therapy. J Cancer Res Ther. 2017;13(6):974–80. https://doi.org/10.4103/0973-1482.220420.

    Article  CAS  PubMed  Google Scholar 

  30. van de Water TA, Bijl HP, Schilstra C, Pijls-Johannesma M, Langendijk JA. The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literature. Oncologist. 2011;16(3):366–77. https://doi.org/10.1634/theoncologist.2010-0171.

    Article  PubMed  PubMed Central  Google Scholar 

  31. • Dagan R, Bryant C, Li Z, Yeung D, Justice J, Dzieglewiski P, et al. Outcomes of Sinonasal Cancer treated with proton therapy. Int J Radiat Oncol Biol Phys. 2016;95(1):377–85. https://doi.org/10.1016/j.ijrobp.2016.02.019 Single institution review from the University of Florida analyzing disease outcomes after proton therapy for sinonasal cancer.

    Article  PubMed  Google Scholar 

  32. • Russo AL, Adams JA, Weyman EA, Busse PM, Goldberg SI, Varvares M, et al. Long-term outcomes after proton beam therapy for sinonasal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2016;95(1):368–76. https://doi.org/10.1016/j.ijrobp.2016.02.042 Single institution review from Massachusetts General Hospital reporting data on long-term outcomes in patients with sinonasal squamous cell carcinoma treated with proton therapy.

    Article  PubMed  Google Scholar 

  33. Zenda S, Kohno R, Kawashima M, Arahira S, Nishio T, Tahara M, et al. Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys. 2011;81(5):1473–8. https://doi.org/10.1016/j.ijrobp.2010.08.009.

    Article  PubMed  Google Scholar 

  34. Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32(25):2735–43. https://doi.org/10.1200/jco.2013.54.6309.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695–704. https://doi.org/10.1056/NEJMoa071028.

    Article  CAS  PubMed  Google Scholar 

  36. LoRusso P, Tapazoglou E, Kish JA, Ensley JF, Cummings G, Kelly J, et al. Chemotherapy for paranasal sinus carcinoma. A 10-year experience at Wayne State University. Cancer. 1988;62(1):1–5. https://doi.org/10.1002/1097-0142(19880701)62:1<1::aid-cncr2820620102>3.0.co;2-f.

    Article  CAS  PubMed  Google Scholar 

  37. Bjork-Eriksson T, Mercke C, Petruson B, Ekholm S. Potential impact on tumor control and organ preservation with cisplatin and 5-fluorouracil for patients with advanced tumors of the paranasal sinuses and nasal fossa. A prospective pilot study. Cancer. 1992;70(11):2615–20. https://doi.org/10.1002/1097-0142(19921201)70:11<2615::aid-cncr2820701108>3.0.co;2-g.

    Article  CAS  PubMed  Google Scholar 

  38. Hanna EY, Cardenas AD, DeMonte F, Roberts D, Kupferman M, Weber R, et al. Induction chemotherapy for advanced squamous cell carcinoma of the paranasal sinuses. Arch Otolaryngol Head Neck Surg. 2011;137(1):78–81. https://doi.org/10.1001/archoto.2010.231.

    Article  PubMed  Google Scholar 

  39. Hoffmann TK. Systemic therapy strategies for head-neck carcinomas: current status. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2012;11:Doc03. https://doi.org/10.3205/cto000085.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Lee MM, Vokes EE, Rosen A, Witt ME, Weichselbaum RR, Haraf DJ. Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am. 1999;5(4):219–23.

    CAS  PubMed  Google Scholar 

  41. Licitra L, Locati LD, Cavina R, Garassino I, Mattavelli F, Pizzi N, et al. Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. Ann Oncol. 2003;14(3):367–72. https://doi.org/10.1093/annonc/mdg113.

    Article  CAS  PubMed  Google Scholar 

  42. Mendenhall WM, Amdur RJ, Morris CG, Kirwan J, Malyapa RS, Vaysberg M, et al. Carcinoma of the nasal cavity and paranasal sinuses. Laryngoscope. 2009;119(5):899–906. https://doi.org/10.1002/lary.20196.

    Article  PubMed  Google Scholar 

  43. Guntinas-Lichius O, Kreppel MP, Stuetzer H, Semrau R, Eckel HE, Mueller RP. Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients. Eur J Surg Oncol. 2007;33(2):222–8. https://doi.org/10.1016/j.ejso.2006.10.033.

    Article  CAS  PubMed  Google Scholar 

  44. Kang JH, Cho SH, Kim JP, Kang KM, Cho KS, Kim W, et al. Treatment outcomes between concurrent chemoradiotherapy and combination of surgery, radiotherapy, and/or chemotherapy in stage III and IV maxillary sinus cancer: multi-institutional retrospective analysis. J Oral Maxillofac Surg. 2012;70(7):1717–23. https://doi.org/10.1016/j.joms.2011.06.221.

    Article  PubMed  Google Scholar 

  45. Kim JH, Lee YS, Chung YS, Jang YJ, Kim SB, Lee SW, et al. Treatment outcomes of concurrent chemoradiotherapy for locally advanced sinonasal squamous cell carcinoma: a single-institution study. Acta Otolaryngol. 2015;135(11):1189–95. https://doi.org/10.3109/00016489.2015.1061697.

    Article  CAS  PubMed  Google Scholar 

  46. Hoppe BS, Nelson CJ, Gomez DR, Stegman LD, Wu AJ, Wolden SL, et al. Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities. Int J Radiat Oncol Biol Phys. 2008;72(3):763–9. https://doi.org/10.1016/j.ijrobp.2008.01.038.

    Article  PubMed  Google Scholar 

  47. Resto VA, Chan AW, Deschler DG, Lin DT. Extent of surgery in the management of locally advanced sinonasal malignancies. Head Neck. 2008;30(2):222–9. https://doi.org/10.1002/hed.20681.

    Article  PubMed  Google Scholar 

  48. Chen NX, Chen L, Wang JL, Wang JY, Yan F, Ma L, et al. A clinical study of multimodal treatment for orbital organ preservation in locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinus. Jpn J Clin Oncol. 2016;46(8):727–34. https://doi.org/10.1093/jjco/hyw064.

    Article  PubMed  Google Scholar 

  49. Danesh-Sani SA, Sarafraz A, Chamani M, Derakhshandeh H. Paranasal sinuses malignancies: a 12-year review of clinical characteristics. Med Oral Patol Oral Cir Bucal. 2016;21(5):e626–30. https://doi.org/10.4317/medoral.21170.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Le QT, Fu KK, Kaplan M, Terris DJ, Fee WE, Goffinet DR. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems. Cancer. 1999;86(9):1700–11.

    Article  CAS  Google Scholar 

  51. Mierzwa ML, Nyati MK, Morgan MA, Lawrence TS. Recent advances in combined modality therapy. Oncologist. 2010;15(4):372–81. https://doi.org/10.1634/theoncologist.2009-S105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. •• Robin TP, Jones BL, Gordon OM, Phan A, Abbott D, McDermott JD, et al. A comprehensive comparative analysis of treatment modalities for sinonasal malignancies. Cancer. 2017;123(16):3040–9. https://doi.org/10.1002/cncr.30686 Recent retrospective analysis of data obtained from National Cancer Data Base of treatment outcomes for over 11,000 patients with sinonasal malignances.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Rosen A, Vokes EE, Scher N, Haraf D, Weichselbaum RR, Panje WR. Locoregionally advanced paranasal sinus carcinoma. Favorable survival with multimodality therapy. Arch Otolaryngol Head Neck Surg. 1993;119(7):743–6. https://doi.org/10.1001/archotol.1993.01880190039008.

    Article  CAS  PubMed  Google Scholar 

  54. • Pare A, Blanchard P, Rosellini S, Auperin A, Gorphe P, Casiraghi O, et al. Outcomes of multimodal management for sinonasal squamous cell carcinoma. J Craniomaxillofac Surg. 2017;45(8):1124–32. https://doi.org/10.1016/j.jcms.2017.05.006 Single institutional data from France suggesting multimodal therapy combining neoadjuvant chemotherapy followed by wide resection and adjuvant radiation therapy seems to provide promising results in management of SCC SNC.

    Article  PubMed  Google Scholar 

  55. Porceddu S, Martin J, Shanker G, Weih L, Russell C, Rischin D, et al. Paranasal sinus tumors: Peter MacCallum Cancer Institute experience. Head Neck. 2004;26(4):322–30. https://doi.org/10.1002/hed.10388.

    Article  PubMed  Google Scholar 

  56. Suarez C, Llorente JL, Fernandez De Leon R, Maseda E, Lopez A. Prognostic factors in sinonasal tumors involving the anterior skull base. Head Neck. 2004;26(2):136–44. https://doi.org/10.1002/hed.10358.

    Article  PubMed  Google Scholar 

  57. Bossi P, Perrone F, Miceli R, Cantu G, Mariani L, Orlandi E, et al. Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. Oral Oncol. 2013;49(5):413–9. https://doi.org/10.1016/j.oraloncology.2012.12.011.

    Article  CAS  PubMed  Google Scholar 

  58. Licitra L, Suardi S, Bossi P, Locati LD, Mariani L, Quattrone P, et al. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol. 2004;22(24):4901–6. https://doi.org/10.1200/jco.2004.05.071.

    Article  CAS  PubMed  Google Scholar 

  59. Reiersen DA, Pahilan ME, Devaiah AK. Meta-analysis of treatment outcomes for sinonasal undifferentiated carcinoma. Otolaryngol Head Neck Surg. 2012;147(1):7–14. https://doi.org/10.1177/0194599812440932.

    Article  PubMed  Google Scholar 

  60. Castelnuovo P, Turri-Zanoni M, Battaglia P, Antognoni P, Bossi P, Locatelli D. Sinonasal malignancies of anterior skull base: histology-driven treatment strategies. Otolaryngol Clin N Am. 2016;49(1):183–200. https://doi.org/10.1016/j.otc.2015.09.012.

    Article  Google Scholar 

  61. Bell D, Hanna EY. Sinonasal undifferentiated carcinoma: morphological heterogeneity, diagnosis, management and biological markers. Expert Rev Anticancer Ther. 2013;13(3):285–96. https://doi.org/10.1586/era.13.1.

    Article  CAS  PubMed  Google Scholar 

  62. Mourad WF, Hauerstock D, Shourbaji RA, Hu KS, Culliney B, Li Z, et al. Trimodality management of sinonasal undifferentiated carcinoma and review of the literature. Am J Clin Oncol. 2013;36(6):584–8. https://doi.org/10.1097/COC.0b013e31825eb3a5.

    Article  PubMed  Google Scholar 

  63. Musy PY, Reibel JF, Levine PA. Sinonasal undifferentiated carcinoma: the search for a better outcome. Laryngoscope. 2002;112(8 Pt 1):1450–5. https://doi.org/10.1097/00005537-200208000-00023.

    Article  PubMed  Google Scholar 

  64. Amit M, Abdelmeguid AS, Watcherporn T, Takahashi H, Tam S, Bell D, et al. Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma. J Clin Oncol. 2019;37(6):504–12. https://doi.org/10.1200/jco.18.00353.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Day TA, Beas RA, Schlosser RJ, Woodworth BA, Barredo J, Sharma AK, et al. Management of paranasal sinus malignancy. Curr Treat Options in Oncol. 2005;6(1):3–18.

    Article  Google Scholar 

  66. Lian B, Si L, Cui C, Chi Z, Sheng X, Mao L, et al. Phase II randomized trial comparing high-dose IFN-alpha2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res. 2013;19(16):4488–98. https://doi.org/10.1158/1078-0432.Ccr-13-0739.

    Article  CAS  PubMed  Google Scholar 

  67. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. Jama. 2011;305(22):2327–34. https://doi.org/10.1001/jama.2011.746.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Valsecchi ME, Sato T. The potential role of sunitinib targeting melanomas. Expert Opin Investig Drugs. 2013;22(11):1473–83. https://doi.org/10.1517/13543784.2013.837449.

    Article  CAS  PubMed  Google Scholar 

  69. Ganti A, Raman A, Shay A, Kuhar HN, Auger SR, Patel T, et al. Treatment modalities in sinonasal mucosal melanoma: a national cancer database analysis. Laryngoscope. 2019. https://doi.org/10.1002/lary.27995.

    Article  Google Scholar 

  70. Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970–1990. Laryngoscope. 1992;102(8):843–9. https://doi.org/10.1288/00005537-199208000-00001.

    Article  CAS  PubMed  Google Scholar 

  71. Eich HT, Hero B, Staar S, Micke O, Seegenschmiedt H, Mattke A, et al. Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in stage C esthesioneuroblastoma. Strahlenther Onkol. 2003;179(4):233–40. https://doi.org/10.1007/s00066-003-1089-x.

    Article  PubMed  Google Scholar 

  72. Loy AH, Reibel JF, Read PW, Thomas CY, Newman SA, Jane JA, et al. Esthesioneuroblastoma: continued follow-up of a single institution’s experience. Arch Otolaryngol Head Neck Surg. 2006;132(2):134–8. https://doi.org/10.1001/archotol.132.2.134.

    Article  PubMed  Google Scholar 

  73. Callender TA, Weber RS, Janjan N, Benjamin R, Zaher M, Wolf P, et al. Rhabdomyosarcoma of the nose and paranasal sinuses in adults and children. Otolaryngol Head Neck Surg. 1995;112(2):252–7. https://doi.org/10.1016/s0194-59989570246-6.

    Article  CAS  PubMed  Google Scholar 

  74. Edmonson JH. Chemotherapeutic approaches to soft tissue sarcomas. Semin Surg Oncol. 1994;10(5):357–63.

    Article  CAS  Google Scholar 

  75. Khan MN, Husain Q, Kanumuri VV, Boghani Z, Patel CR, Liu JK, et al. Management of sinonasal chondrosarcoma: a systematic review of 161 patients. Int Forum Allergy Rhinol. 2013;3(8):670–7. https://doi.org/10.1002/alr.21162.

    Article  PubMed  Google Scholar 

  76. van den Berg H, Schreuder WH, de Lange J. Osteosarcoma: a comparison of jaw versus nonjaw localizations and review of the literature. Sarcoma. 2013;2013:316123. https://doi.org/10.1155/2013/316123.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Scangas GA, Eloy JA, Lin DT. The role of chemotherapy in the management of sinonasal and ventral skull base malignancies. Otolaryngol Clin N Am. 2017;50(2):433–41. https://doi.org/10.1016/j.otc.2016.12.015.

    Article  Google Scholar 

Download references

Contributions

Dr. Mody contributed as a primary author and Dr. Saba contributed as senior author and editor.

Author information

Authors and Affiliations

  1. Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA

    Mayur D. Mody MD & Nabil F. Saba MD, FACP

  2. Winship Cancer Institute of Emory University, Atlanta, GA, USA

    Mayur D. Mody MD & Nabil F. Saba MD, FACP

Authors
  1. Mayur D. Mody MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nabil F. Saba MD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nabil F. Saba MD, FACP.

Ethics declarations

Conflict of Interest

Mayur D. Mody declares that he has no conflict of interest. Nabil F. Saba has received research funding from Bristol-Myers Squibb, Exelixis, and Champions Oncology; has served on advisory boards for Merck, Bristol-Myers Squibb, Rakuten, and GlaxoSmithKline; and has served on a data safety monitoring committee for Amgen.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Head and Neck Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mody, M.D., Saba, N.F. Multimodal Therapy for Sinonasal Malignancies: Updates and Review of Current Treatment. Curr. Treat. Options in Oncol. 21, 4 (2020). https://doi.org/10.1007/s11864-019-0696-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-019-0696-4

Keywords

Search

Navigation